-
EP2849793
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2849793
| EP2849793 - AFFINITY PEPTIDES TOWARD INFLIXIMAB [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 03.05.2024 Database last updated on 09.07.2024 | |
| Former | Grant of patent is intended Status updated on 31.08.2023 | ||
| Former | Examination is in progress Status updated on 29.06.2019 | Most recent event Tooltip | 03.05.2024 | Application deemed to be withdrawn | published on 05.06.2024 [2024/23] | Applicant(s) | For all designated states Janssen Biotech, Inc. 800/850 Ridgeview Drive Horsham, PA 19044 / US | [2015/13] | Inventor(s) | 01 /
SALICK RYAN, Daphne Ann 1400 McKean Road Spring House, PA / US | 02 /
KEHOE, John 1400 McKean Road Spring House, PA / US | 03 /
WHEELER, John 1400 McKean Road Spring House, PA / US | 04 /
YANG, Chunlin 409 Illinois Street San Francisco, CA 94158 / US | 05 /
CREASEY, Abla 920 Route 202 South Raritan, NJ 08876 / US | [2015/13] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2015/13] | Application number, filing date | 13790843.0 | 15.05.2013 | WO2013US41062 | Priority number, date | US201213474056 | 17.05.2012 Original published format: US201213474056 | [2015/13] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2013173410 | Date: | 21.11.2013 | Language: | EN | [2013/47] | Type: | A2 Application without search report | No.: | EP2849793 | Date: | 25.03.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 21.11.2013 takes the place of the publication of the European patent application. | [2015/13] | Search report(s) | International search report - published on: | US | 23.01.2014 | (Supplementary) European search report - dispatched on: | EP | 28.09.2016 | Classification | IPC: | A61K47/30, C07K14/525, C07K7/08, A61K39/00, A61K47/42, C07K16/24, A61K39/395 | [2016/21] | CPC: |
C07K16/241 (EP,US);
A61K47/42 (US);
A61K39/3955 (US);
A61P1/04 (EP);
A61P17/02 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P29/00 (EP);
A61P43/00 (EP);
C07K14/525 (EP,US);
C07K7/08 (EP,US);
A61K2039/505 (US);
|
| Former IPC [2015/13] | A61K47/30 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/13] | Title | German: | INFLIXIMAB-AFFINITÄTSPEPTIDE | [2015/13] | English: | AFFINITY PEPTIDES TOWARD INFLIXIMAB | [2015/13] | French: | PEPTIDES AYANT UNE AFFINITÉ POUR L'INFLIXIMAB | [2015/13] | Entry into regional phase | 17.12.2014 | National basic fee paid | 17.12.2014 | Search fee paid | 17.12.2014 | Designation fee(s) paid | 17.12.2014 | Examination fee paid | Examination procedure | 17.12.2014 | Examination requested [2015/13] | 21.04.2017 | Amendment by applicant (claims and/or description) | 03.07.2019 | Despatch of a communication from the examining division (Time limit: M04) | 11.11.2019 | Reply to a communication from the examining division | 23.07.2020 | Despatch of a communication from the examining division (Time limit: M06) | 27.04.2021 | Reply to a communication from the examining division | 01.09.2023 | Communication of intention to grant the patent | 12.01.2024 | Application deemed to be withdrawn, date of legal effect [2024/23] | 01.02.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2024/23] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 03.07.2019 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 27.04.2021 | Request for further processing filed | 27.04.2021 | Full payment received (date of receipt of payment) Request granted | 06.05.2021 | Decision despatched | Fees paid | Renewal fee | 12.05.2015 | Renewal fee patent year 03 | 10.05.2016 | Renewal fee patent year 04 | 10.05.2017 | Renewal fee patent year 05 | 11.05.2018 | Renewal fee patent year 06 | 15.05.2019 | Renewal fee patent year 07 | 31.03.2020 | Renewal fee patent year 08 | 13.05.2021 | Renewal fee patent year 09 | 14.03.2022 | Renewal fee patent year 10 | 21.03.2023 | Renewal fee patent year 11 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2009121024 (UNIV CALIFORNIA [US], et al) [Y] 1-15 * paragraph [0043]; claims 1-26 * * abstract *; | [Y]US2011230406 (KEHOE JOHN [US], et al) [Y] 1-15 * figures 1-15; examples 1-13; claims 1-10 *; | [A] - IRVING M B ET AL, "Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 47, no. 5, ISSN 0161-5890, (20100201), pages 1137 - 1148, (20100201), XP027036622 [A] 1-15 * the whole document * | [A] - KAY B K ET AL, "Screening phage-displayed combinatorial peptide libraries", METHODS, ACADEMIC PRESS, US, (20010701), vol. 24, no. 3, doi:10.1006/METH.2001.1185, ISSN 1046-2023, pages 240 - 246, XP002257757 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1006/meth.2001.1185 | [Y] - JANSSON B ET AL, "All individual domains of staphylococcal protein A show Fab binding", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, (19980101), vol. 20, no. 1, doi:10.1016/S0928-8244(97)00108-9, ISSN 0928-8244, pages 69 - 78, XP002284946 [Y] 1-15 * abstract * DOI: http://dx.doi.org/10.1016/S0928-8244(97)00108-9 | [XY] - MIHA KOSMAC ET AL, "Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients With Rheumatic Diseases Treated With Infliximab", PEDIATRIC RESEARCH, (20110301), vol. 69, no. 3, doi:10.1203/PDR.0b013e318208451d, ISSN 0031-3998, pages 243 - 248, XP055178456 [X] 4-9,13,15 * abstract, table 1, page 243 to 245, Methods;page 244, column 2, last paragraph; page 247 * [Y] 1-3,10,12,14 DOI: http://dx.doi.org/10.1203/PDR.0b013e318208451d | International search | [Y]US5510418 (RHEE WOONZA M [US], et al); | [A]US2006008532 (GOVARDHAN CHANDRIKA [US], et al); | [A]US2009304719 (DAUGHERTY PATRICK [US], et al); | [A]US2010112070 (ELIAZ ROM EZER [US], et al); | [X] - KOSMAC ET AL., "Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients with Rheumatic Diseases Treated with Infliximab.", PEDIATR RES., (201103), vol. 69, no. 3, pages 243 - 248, XP055178456 DOI: http://dx.doi.org/10.1203/PDR.0b013e318208451d |